Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.

Hiroe Kayatani,Keisuke Aoe,Kadoaki Ohashi,Hiroshige Yoshioka,Akihiro Bessho,Nobuhisa Ishikawa,Masahiro Yamasaki,Toshiyuki Kozuki,Nobukazu Fujimoto,Y. Ueda,Syuuji Bandoh,Isao Murakami,Hirohisa Ichikawa,Tetsuya Kubota,Keisuke Sugimoto,Nagio Takigawa,Takashi Sumikawa,Katsuyuki Kiura

Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.

2019

Hiroe Kayatani
Keisuke Aoe
Kadoaki Ohashi
Hiroshige Yoshioka
Akihiro Bessho
Nobuhisa Ishikawa
Masahiro Yamasaki
Toshiyuki Kozuki
Nobukazu Fujimoto
Y. Ueda
Syuuji Bandoh
Isao Murakami
Hirohisa Ichikawa
Tetsuya Kubota
Keisuke Sugimoto
Nagio Takigawa
Takashi Sumikawa
Katsuyuki Kiura

9056Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a key treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC). To date, a biomarker to predict...

Keywords:

Subset Analysis
Epidermal growth factor receptor
Cancer research
Carcinoma
Pathology
Biomarker (medicine)
Medicine
Tyrosine kinase
Lung
egfr mutation
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations